{name}
{subtitle}
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~19 mi. (Regensburg, Germany, +93 more cities)
facility
Caritas Krankenhaus St. Josef ( Site 0502)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~19 mi. (Regensburg, Germany, +127 more cities)
facility
Universitaetsklinikum Regensburg ( Site 2100)
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
city
~19 mi. (Regensburg, Germany, +25 more cities)
facility
Universitaetsklinikum Regensburg ( Site 2007)
drug
coxsackievirus A21, +1 more drug
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
city
~19 mi. (Regensburg, Germany, +16 more cities)
facility
Site DE49003
drug
cytarabine, +3 more drugs
drug type
chemotherapy, +2 more types
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
city
~48 mi. (Amberg, Germany, +144 more cities)
facility
GSK Investigational Site
drug
carboplatin, +3 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~60 mi. (Neumarkt in der Oberpfalz, Germany, +130 more cities)
facility
Klinikum Weiden ( Site 0259)
drug
BCG solution, +1 more drug
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~73 mi. (München, Germany, +192 more cities)
facility
Klinikum der Universität München Großhadern, +1 more facility
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type